[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ: Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ; 2007 Sep 29;335(7621):651
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study.
  • OBJECTIVE: To examine the absolute risks or benefits on cancer associated with oral contraception, using incident data.
  • MAIN OUTCOME MEASURES: Adjusted relative risks between never and ever users of oral contraceptives for different types of cancer, main gynaecological cancers combined, and any cancer.
  • Standardisation variables were age, smoking, parity, social class, and (for the general practitioner observation dataset) hormone replacement therapy.
  • Subgroup analyses examined whether the relative risks changed with user characteristics, duration of oral contraception usage, and time since last use of oral contraception.
  • Compared with never users ever users had statistically significant lower rates of cancers of the large bowel or rectum, uterine body, and ovaries, tumours of unknown site, and other malignancies; main gynaecological cancers combined; and any cancer.
  • The relative risk for any cancer in the smaller general practitioner observation dataset was not significantly reduced.
  • Statistically significant trends of increasing risk of cervical and central nervous system or pituitary cancer, and decreasing risk of uterine body and ovarian malignancies, were seen with increasing duration of oral contraceptive use.
  • Reduced relative risk estimates were observed for ovarian and uterine body cancer many years after stopping oral contraception, although some were not statistically significant.
  • The estimated absolute rate reduction of any cancer among ever users was 45 or 10 per 100,000 woman years, depending on whether the main or general practitioner observation dataset was used.
  • CONCLUSION: In this UK cohort, oral contraception was not associated with an overall increased risk of cancer; indeed it may even produce a net public health gain.
  • The balance of cancer risks and benefits, however, may vary internationally, depending on patterns of oral contraception usage and the incidence of different cancers.


2. Jordan VC, Gapstur S, Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst; 2001 Oct 3;93(19):1449-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
  • SERMs also have different degrees of estrogenicity in the uterus.
  • Tamoxifen is used specifically to reduce the incidence of breast cancer in premenopausal and postmenopausal women at risk for the disease.
  • The study of tamoxifen and raloxifene (STAR) trial is currently comparing the ability of these SERMs to reduce breast cancer incidence in high-risk postmenopausal women.
  • There is intense interest in understanding the molecular mechanism(s) of action of SERMs at target sites in a woman's body.
  • An understanding of the targeted actions of this novel drug group will potentially result in the introduction of new multifunctional medicines with applications as preventive agents or treatments of breast cancer and endometrial cancer, coronary heart disease, and osteoporosis.
  • [MeSH-major] Breast Neoplasms / prevention & control. Coronary Disease / prevention & control. Osteoporosis / prevention & control. Selective Estrogen Receptor Modulators / therapeutic use
  • [MeSH-minor] Adult. Aged. Bone and Bones / drug effects. Breast / drug effects. Cardiovascular System / drug effects. Cinnamates / pharmacology. Clinical Trials as Topic. Endometrial Neoplasms / chemically induced. Estrogen Replacement Therapy. Female. Heart / drug effects. Hot Flashes / chemically induced. Humans. Middle Aged. Models, Biological. Organ Specificity. Postmenopause. Premenopause. Prospective Studies. Protein Structure, Tertiary / drug effects. Raloxifene Hydrochloride / adverse effects. Raloxifene Hydrochloride / pharmacology. Raloxifene Hydrochloride / therapeutic use. Randomized Controlled Trials as Topic. Receptors, Estrogen / analysis. Receptors, Estrogen / drug effects. Risk. Risk Assessment. Stilbenes / pharmacology. Tamoxifen / adverse effects. Tamoxifen / pharmacology. Tamoxifen / therapeutic use. Thrombophilia / chemically induced. Transcription, Genetic / drug effects

  • Genetic Alliance. consumer health - Heart Disease.
  • Genetic Alliance. consumer health - Osteoporosis.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. RALOXIFENE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584060.001).
  • [ISSN] 0027-8874
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89018-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cinnamates; 0 / GW 7604; 0 / Receptors, Estrogen; 0 / Selective Estrogen Receptor Modulators; 0 / Stilbenes; 094ZI81Y45 / Tamoxifen; 4F86W47BR6 / Raloxifene Hydrochloride
  • [Number-of-references] 96
  •  go-up   go-down


3. Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, Okada H, Maeda M, Ouchi Y: FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun; 2006 Jun;27(6):481-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer.
  • OBJECTIVE: For surgical planning of uterine corpus cancer, prior knowledge of the depth of myometrial invasion is important.
  • Curative tumour resection is possible in superficial invasion (stages IA and IB), while post-surgical chemotherapy or radiation therapy is required in deep invasion (stage IC).
  • We evaluated the value of positron emission tomography with 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG PET) for estimating the myometrial invasion in uterine corpus cancer.
  • METHODS: We studied 22 patients with clinical stage I uterine corpus cancer, who underwent FDG PET prior to surgery.
  • Standardized uptake value (SUV; tracer activity per injected dose normalized to body weight) was calculated on the PET image.
  • FDG PET may be feasible for predicting the myometrial infiltration of uterine corpus cancer, especially when uterine atrophy makes it difficult at MRI in post-menopausal patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Myometrium / pathology. Myometrium / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Uterine Neoplasms / pathology. Uterine Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness. Preoperative Care / methods. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710101.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Sairam MR, Danilovich N, Lussier-Cacan S: The FORKO mouse as a genetic model for exploring estrogen replacement therapy. J Reprod Med; 2002 May;47(5):412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The FORKO mouse as a genetic model for exploring estrogen replacement therapy.
  • OBJECTIVE: To evaluate how chronically estrogen deficient female FORKO mice with genetic disruption of the FSH receptor respond to estrogen therapy.
  • STUDY DESIGN: Subcutaneous estrogen agonist or antagonist therapy was initiated to study reproductive tissue response, adipose tissue mass and plasma lipid profiles.
  • RESULTS: Within 36-48 hours of agonist administration, the classic measures of estrogenic activity were evident in the uterus and vagina.
  • Older animals also responded to therapy during a 10-day period, indicating that estrogen receptor signaling systems are unaffected by aging.
  • In these obese mutants, this short treatment decreased adipose tissue in all areas and corrected lipid abnormalities.
  • Tamoxifen, a nonsteroidal mixed estrogen agonist and antagonist, had marginal effects on the uterus and body fat of FORKO mice, indicating differences in interaction.
  • Hence, this is a useful model for studying estrogen replacement therapy and helps resolve questions related to efficacy and actions.
  • [MeSH-major] Disease Models, Animal. Estradiol / pharmacology. Estrogen Antagonists / pharmacology. Estrogen Replacement Therapy. Tamoxifen / pharmacology
  • [MeSH-minor] Adipose Tissue / drug effects. Animals. Apolipoproteins E / blood. Cholesterol / blood. Cholesterol, HDL / blood. Female. Mice. Mice, Knockout. Models, Genetic. Receptors, FSH / deficiency. Receptors, FSH / genetics. Testosterone / blood. Triglycerides / blood. Uterus / drug effects. Vagina / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063881.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Cholesterol, HDL; 0 / Estrogen Antagonists; 0 / Receptors, FSH; 0 / Triglycerides; 094ZI81Y45 / Tamoxifen; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


5. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC: Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science; 2002 Oct 25;298(5594):843-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classical genotropic actions of sex steroid receptors are dispensable for their bone protective effects, but essential for their effects on reproductive tissues.
  • Such ligands merit investigation as potential therapeutic alternatives to hormone replacement for osteoporosis in both women and men [corrected].
  • [MeSH-major] Bone Density / drug effects. Bone and Bones / drug effects. Estrenes / pharmacology. Osteoblasts / drug effects. Osteoclasts / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Body Weight / drug effects. Breast Neoplasms / pathology. Cell Division / drug effects. Cells, Cultured. Compressive Strength / drug effects. Dihydrotestosterone / pharmacology. Estradiol / pharmacology. Female. Humans. Male. Mice. Orchiectomy. Organ Size / drug effects. Osteocalcin / blood. Osteogenesis / drug effects. Osteoporosis / drug therapy. Ovariectomy. Pyrazoles / pharmacology. Receptors, Estrogen / metabolism. Seminal Vesicles / drug effects. Transcription, Genetic / drug effects. Tumor Cells, Cultured. Uterus / drug effects. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Bone Density.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Science. 2002 Oct 25;298(5594):723-4 [12399556.001]
  • [ErratumIn] Science. 2003 Feb 21;299(5610):1184
  • (PMID = 12399595.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / KO2-AR02127; United States / NIA NIH HHS / AG / P01-AG13918
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-estren-3,17-diol; 0 / Estrenes; 0 / Pyrazoles; 0 / Receptors, Estrogen; 08J2K08A3Y / Dihydrotestosterone; 104982-03-8 / Osteocalcin; 3QD5KJZ7ZJ / pyrazole; 4TI98Z838E / Estradiol
  •  go-up   go-down


6. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN: Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke; 2002 Jun;33(6):1685-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone.
  • BACKGROUND AND PURPOSE: In vivo and in vitro rat models of hormone therapy were used to test the following hypotheses:.
  • (2) increased protein correlates with higher NOS activity; and (3) effects of estrogen on eNOS are altered by concurrent treatment with either medroxyprogesterone acetate (MPA) or progesterone.
  • Levels of eNOS were measured by Western blot, and NOS activity was measured by [14C]arginine-[14C]citrulline conversion.
  • RESULTS: Chronic hormone treatment in vivo resulted in plasma levels of 17beta-estradiol, progesterone, and MPA in the range of values found in humans.
  • Estrogen treatment resulted in higher levels of cerebrovascular NOS activity that paralleled increases in eNOS protein.
  • In vitro estrogen treatment for 18 hours also resulted in a concentration-dependent increase in eNOS protein (EC50 approximately 300 pmol/L) that was completely prevented by estrogen receptor antagonists tamoxifen or ICI 182 780.
  • CONCLUSIONS: Estrogen receptor activation in cerebrovascular tissue results in increased eNOS activity and protein levels.
  • [MeSH-minor] Animals. Body Weight / drug effects. Brain / blood supply. Dose-Response Relationship, Drug. Drug Implants. Enzyme Activation / drug effects. Estrogen Replacement Therapy. Female. In Vitro Techniques. Models, Animal. Nitric Oxide Synthase Type III. Organ Size / drug effects. Ovariectomy. Rats. Rats, Inbred F344. Tamoxifen / pharmacology. Uterus / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12053012.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL50775
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Estrogens; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; 22X328QOC4 / fulvestrant; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.14.13.39 / Nos3 protein, rat
  •  go-up   go-down


7. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr: Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst; 2004 Jan 7;96(1):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.
  • Recent studies have indicated that the tamoxifen-related risk of uterine corpus cancer may be especially high for some uncommon cell types, although the magnitude of risk has not been quantified.
  • We evaluated data from 39 451 breast cancer patients diagnosed from 1980 through 2000 who were initially treated with tamoxifen and found that the overall risk of subsequent uterine corpus cancer was increased more than twofold (observed-to-expected ratio [O/E] = 2.17, 95% confidence interval [CI] = 1.95 to 2.41) relative to the general SEER population.
  • The relative risk was substantially higher for malignant mixed mullerian tumors (MMMTs) (O/E = 4.62, O = 34, 95% CI = 3.20 to 6.46) than for endometrial adenocarcinomas (O/E = 2.07, O = 306, 95% CI = 1.85 to 2.32), although the excess absolute risk was smaller-an additional 1.4 versus 8.4 cancers per 10 000 women per year, respectively.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Estrogen Receptor Modulators / adverse effects. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adult. Aged. Carcinoma, Ductal / drug therapy. Confidence Intervals. Female. Humans. Middle Aged. Odds Ratio. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14709741.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


8. Tanase Y, Kawaguchi R, Haruta S, Kanayama S, Yamada Y, Kobayashi H: [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide]. Gan To Kagaku Ryoho; 2006 Jul;33(7):945-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide].
  • The therapeutic efficacy and adverse reactions were compared between 14 patients who received TJ therapy using paclitaxel (PTX) and carboplatin (CBDCA) and 39 who received CAP therapy using cyclophosphamide (CPA), doxorubicin (DXR) and cisplatin (CDDP) as postoperative chemotherapy for cancer of the uterine body.
  • In TJ therapy, PTX (175 mg/m(2)) and CBDCA (AUC 5) were administered on Day 1 (every 3 weeks), while in CAP therapy, CPA (500 mg/m(2)), DXR (40 mg/m(2)) and CDDP (50 mg/m(2)) were administered on Day 1 (every 4 weeks).
  • Grade 3 or severe non-hematologic toxicities included nausea (0%, 15.4%) and vomiting (0%, 12.8%) with significantly higher incidence in the CAP therapy group (p=0.0000736, p=0.000736), peripheral sensory disturbance (7.1%, 0%) and arthralgia (7.1%, 0%) with significantly higher incidence in the TJ therapy group (p=0.00129, p=0.00000538).
  • TJ therapy is thought to be as effective as CAP therapy, and can be safely conducted, although precautions are required regarding arthralgia and neuropathy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterectomy. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835485.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Inoue M: [Prognostic factors uterine corpus cancer]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2008-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors uterine corpus cancer].
  • FIGO staging has taken into consideration of the tumor expansion and is the most important predictor in evaluating patient outcome.
  • Characteristics of tumor biology, such as morphology of tumor and depth of invasion are also important prognostic considerations.
  • Molecular markers indicating genetic/molecular events in cancer biology appear to be the 3rd predictors in estimating the prognosis.
  • Finally, treatment of uterine corpus cancer can be directly related to prognosis.
  • Postoperative chemotherapy is gradually taking precedence over irradiation in considering evidence-based medicine.
  • [MeSH-major] Lymph Nodes / pathology. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197744.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


10. Thawornkaiwong A, Preawnim S, Wattanapermpool J: Upregulation of beta 1-adrenergic receptors in ovariectomized rat hearts. Life Sci; 2003 Mar 7;72(16):1813-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in cardiac myofilament Ca(2+) activation have been demonstrated in ovariectomized rats.
  • Subcutaneous injection of estrogen (5 microg/rat), progesterone (1 mg/rat), or estrogen plus progesterone three times a week all effectively prevented the upregulation of the beta(1)-adrenoceptors.
  • [MeSH-minor] Adrenergic beta-1 Receptor Antagonists. Animals. Body Weight / drug effects. Drug Therapy, Combination. Estrogens / administration & dosage. Estrogens / pharmacology. Female. Heart / drug effects. Immunoblotting. Injections, Subcutaneous. Organ Size / drug effects. Progesterone / administration & dosage. Progesterone / pharmacology. Rats. Rats, Sprague-Dawley. Sarcolemma / metabolism. Up-Regulation. Uterus / drug effects

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12586219.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-1 Receptor Antagonists; 0 / Estrogens; 0 / Receptors, Adrenergic, beta-1; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


11. Tsai MH, Huang GS, Hung YC, Bin L, Liao LT, Lin LW: Psoralea corylifolia extract ameliorates experimental osteoporosis in ovariectomized rats. Am J Chin Med; 2007;35(4):669-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCL extract (25 mg or 50 mg/kg body weight/day) was orally administrated to OVX rats for 3 months.
  • PCL extract did not alter weight gain or uterus weight in OVX rats.
  • PCL extract significantly increased serum Ca (calcium) levels (p < 0.05, vs.
  • OVX group) as well as decreased urinary Ca excretion (p < 0.05 vs. OVX group) in OVX rats.
  • The upregulation of serum osteocalcin level by ovariectomy was suppressed by treatment with PCL extract in rats (p < 0.05, vs. OVX group).
  • PCL extract increased bone mineral density at 50 mg/kg body weight/day in OVX rats (p < 0.05, vs. OVX group).
  • In conclusion, our studies showed that PCL might be a potential candidate for treatment of postmenopausal osteoporosis.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Osteoporosis / etiology. Osteoporosis / prevention & control. Ovariectomy / adverse effects. Psoralea
  • [MeSH-minor] Administration, Oral. Animals. Bone Density / drug effects. Bone Density / physiology. Bone Resorption / drug therapy. Bone and Bones / metabolism. Bone and Bones / pathology. Calcium / metabolism. Disease Models, Animal. Female. Osteocalcin / blood. Osteogenesis / drug effects. Phytotherapy / methods. Random Allocation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708633.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 104982-03-8 / Osteocalcin; SY7Q814VUP / Calcium
  •  go-up   go-down


12. Teplitzky SR, Kiefer TL, Cheng Q, Dwivedi PD, Moroz K, Myers L, Anderson MB, Collins A, Dai J, Yuan L, Spriggs LL, Blask DE, Hill SM: Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett; 2001 Jul 26;168(2):155-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid.
  • In experimental trials using the N-nitroso-N-methylurea (NMU)-induced rat mammary tumor model, a significant decrease in tumor incidence (to 5%) was observed in rats treated with melatonin and 9-cis-retinoic acid (9 cRA) compared to controls (55%).
  • Although 9cRA alone decreased tumor incidence to 26%, this response did not reach statistical significance.
  • Tumor incidence was significantly inhibited to 20% in the animals that received melatonin and 9cRA on alternating days.
  • Latency to tumor onset was prolonged in animals receiving either of the combination treatments compared with controls, and tumor multiplicity was also significantly decreased.
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Body Weight / drug effects. Carcinogens / antagonists & inhibitors. Drug Synergism. Drug Therapy, Combination. Estradiol / blood. Estrogen Receptor alpha. Female. Free Radical Scavengers / pharmacology. Methylnitrosourea. Organ Size / drug effects. Rats. Rats, Sprague-Dawley. Receptors, Estrogen / biosynthesis. Receptors, Retinoic Acid / biosynthesis. Uterus / anatomy & histology. Uterus / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ALITRETINOIN .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11403920.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01CA54152-07; United States / NCI NIH HHS / CA / R01CA76197; United States / NCI NIH HHS / CA / T32CAC5436-01A3
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Free Radical Scavengers; 0 / Receptors, Estrogen; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 4TI98Z838E / Estradiol; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin; 684-93-5 / Methylnitrosourea; JL5DK93RCL / Melatonin
  •  go-up   go-down


13. Hara K, Tada M, Naruse S, Soma Y, Kojima Y, Kurata H, Tanaka K, Tsuji S: [Two cases of lumbosacral radiculopathy after intra-arterial infusion of cisplatin for treatment of uterine cancer]. Rinsho Shinkeigaku; 2003 Jan-Feb;43(1-2):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of lumbosacral radiculopathy after intra-arterial infusion of cisplatin for treatment of uterine cancer].
  • A 60-year-old woman (case 1) experienced severe pain in the lower part of her leg and sciatic nerve paralysis the following day after intra-arterial infusion of cisplatin for the treatment of uterine body cancer.
  • A 49-year-old woman (case 2) complained of severe pain in the lower part of her leg three days after intra-arterial infusion of cisplatin for the treatment of uterocervical cancer.
  • The symptoms gradually improved with the symptomatic therapy.
  • It was suggested that lumbo-sacral radiculopathy induced by intra-arterial infusion of cisplatin is not a rare complication and that MRI is useful in confirming the diagnosis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cisplatin / adverse effects. Radiculopathy / chemically induced. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Infusions, Intra-Arterial. Lumbosacral Region. Magnetic Resonance Imaging. Middle Aged. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820547.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshò„ shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down






Advertisement